59875-04-6

Basic information

• Product Name: 2-Butyrylaminopropinicacid
• Synonyms: 2-Butyrylaminopropinicacid;Alanin, N-(1-oxobutyl)-;2-Butyramidopropanoic acid;DL-Alanine, N-(1-oxobutyl)-;2-((Butanoyl)amino)propanoic acid;N-(1-Oxobutyl)alanine;N-(1-Oxobutyl)-DL-alanine;Alanine,N-(1-oxobutyl)-
• CAS NO: 59875-04-6
• Molecular Formula: C₇H₁₃NO₃
• Molecular Weight: 159.18
• EINECS: 1592732-453-0
• Mol File: 59875-04-6.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 371.8 °C at 760 mmHg
• Flash Point: 178.7 °C
• Appearance: /
• Density: 1.097
• Vapor Pressure: 1.5E-06mmHg at 25°C
• Refractive Index: 1.458
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• Solubility: DMSO, Methanol
• PKA: 3.69±0.10(Predicted)
• CAS DataBase Reference: 2-Butyrylaminopropinicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Butyrylaminopropinicacid(59875-04-6)
• EPA Substance Registry System: 2-Butyrylaminopropinicacid(59875-04-6)

Safety Data

• Hazardous Substances Data: 59875-04-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Butyrylaminopropinic acid is used as a reactant for the preparation of Vardenafil (V098001, 2HCl salt), a selective phosphodiesterase type 5 (PDE5) inhibitor. This application is significant because Vardenafil is a widely used medication for the treatment of erectile dysfunction, helping to improve blood flow to the penis and facilitating an erection in response to sexual stimulation. By acting as a reactant in the synthesis of Vardenafil, 2-Butyrylaminopropinic acid plays a vital role in the development of this therapeutic agent, ultimately contributing to the improvement of patients' quality of life and overall well-being.

InChI:InChI=1/C7H13NO3/c1-3-4-6(9)8-5(2)7(10)11/h5H,3-4H2,1-2H3,(H,8,9)(H,10,11)

Upstream product

• 56-41-7 L-alanin 
• 141-75-3 butyryl chloride 
• 302-72-7 rac-Ala-OH 

Downstream Products

• 1134191-22-2 4-(5-thioxo-5H-1,2-dithiol-3-yl)phenyl 2-(4-(4-ethoxy-3-(5-methyl-4-oxo-7-propyl-1,4-dihydroimidazo[1,5-f][1,2,4]triazin-2-yl)phenylsulfonyl)piperazin-1-yl)acetate 
• 1134191-27-7 2-(4-(4-ethoxy-3-(5-methyl-4-oxo-7-propyl-1,4-dihydroimidazo[1,5-f][1,2,4]triazin-2-yl)phenylsulfonyl)piperazin-1-yl)acetic acid 
• 1134191-30-2 C₂₅H₃₄N₆O₆S 
• 224789-26-8 4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)benzenesulfonic acid chloride 
• 224789-21-3 2-(2-ethoxyphenyl)-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 224785-90-4 vardenafil 
• 224789-21-3 2-(2-ethoxy-phenyl)-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 927690-90-2 N-{1-[3-(2-ethoxyphenyl)-5-oxo-4,5-dihydro-[1,2,4]triazin-6-yl]ethyl}butyroamide 

Relevant articles and documents

NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT

Novel compounds for use in cognition improvement It relates to certain compounds having a polycyclic structure and a -(C=O)NRaRb moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases.

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):

N-BUTYRAMIDE, THE PREPARATION METHOD AND USE THEREOF

Disclosed are N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)sulfonylphenyl)-4,5-dihydro-5-oxo-1,2,4-triazin-6-yl]ethyl}butyramide (which is represented by formula III), its preparation method, intermediates during preparation procedure, preparation method for such intermediates and a method for preparing vardenafil from the compound. In the method for preparing vardenafil, a chloro-sulfonation reaction carries out in the early stage of the preparation procedure.

PROCESSES FOR THE PREPARATION OF VARDENAFIL

The present invention provides processes for the preparation of vardenafil, its pharmaceutically acceptable salts, hydrates and intermediates.

N-{1-Y3-(2-ETHOXY-5-(4-ETHYLPIPERAZINYL)BENZENESULFONYL)-4,5-DIHYDRO-5-OXO-1,2,4-TRIAZIN-6-YL¨ETHYL}BUTYRAMIDE, THE PREPARATION METHOD AND USE THEREOF

Disclosed are N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)sulfonylphenyl)-4,5-dihydro-5-oxo-1,2,4-triazin-6-yl]ethyl}butyramide (which is represented by formula III), its preparation method, intermediates during preparation procedure, preparation method for such intermediates and a method for preparing vardenafil from the compound. In the method for preparing vardenafil, a chloro-sulfonation reaction carries out in the early stage of the preparation procedure.

An improved synthetic route for preparative process of vardenafil

A new, convergent synthetic route for the process optimization of vardenafil (Levitra), a potent and effective PDE5 inhibitor, is described. Key improved steps in the preparative process are that the chlorosulfonation reaction is at the beginning and the dehydration-cyclisation reaction is at a later stage so that the synthetic route has a better overall yield and simpler workup operations. The yield of vardenafil produced from this synthetic route is around 45% over seven steps with purity at 99.2% (HPLC).

NEW AGENTS FOR THE TREATMENT OF THE LOW URINARY TRACT DYSFUNCTIONS

The present invention relates to novel compounds that are derivatives of 5 -phosphodiesterase inhibitors that comprise in their formula a polysulfurated group and that are useful for treating dysfunctions of low urinary tract such as incontinence, benign prostatic hyperplasia and erectile dysfunction.

Novel imidazotriazinones and the use thereof

Novel imidazotrizinones of general formula (I), a method for the production and the pharmaceutical use thereof are disclosed.

2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors

The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.

Process for the preparation of sulphonamide-substituted imidazotriazinones

The present invention relates to a process for the preparation of sulphonamide-substituted imidazotriazinones of the general formula (I) characterized in that compounds of the formula (II) are reacted with sulphuric acid and the products obtained are then reacted with thionyl chloride and converted in situ in an inert solvent using an amine into the compounds according to the invention and, if appropriate, reacted to give the corresponding salts, hydrates or N-oxides.